American Century Companies’s Stoke Therapeutics STOK Stock Holding History

American Century Companies’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,397	Closed	-$762K	–	2994
2026 Q1	$762K	Sell	23,397 -91,721	-80%	-$3.01M	﹤0.01%	2408
2025 Q4	$3.65M	Buy	115,118 +16,026	+16%	+$482K	﹤0.01%	1866
2025 Q3	$2.33M	Buy	99,092 +71,753	+262%	+$1.23M	﹤0.01%	2012
2025 Q2	$310K	Buy	+27,339	New	+$260K	﹤0.01%	2657
2024 Q3	–	Sell	-59,149	Closed	-$799K	–	2955
2024 Q2	$799K	Buy	59,149 +29,489	+99%	+$398K	﹤0.01%	2260
2024 Q1	$400K	Buy	29,660 +8,624	+41%	+$52.2K	﹤0.01%	2528
2023 Q4	$111K	Buy	21,036 +4,893	+30%	+$20.9K	﹤0.01%	2804
2023 Q3	$63.6K	Buy	+16,143	New	+$106K	﹤0.01%	2777
2020 Q1	–	Sell	-143,327	Closed	-$4.06M	–	1713
2019 Q4	$4.06M	Buy	143,327 +54,572	+61%	+$1.37M	﹤0.01%	836
2019 Q3	$1.91M	Sell	88,755 -16,128	-15%	-$450K	﹤0.01%	977
2019 Q2	$3.06M	Buy	+104,883	New	+$2.82M	﹤0.01%	944

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies's STOK Position: Q2 2026 in Review

American Century Companies sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 23,397 shares — an estimated $762K sold.

American Century Companies first reported a position in STOK in Q2 2019 and held it in 11 quarters. The position peaked at $4.06M in Q4 2019. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

American Century Companies reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
American Century Companies sold 23,397 Stoke Therapeutics shares in Q2 2026, an estimated $762K.
American Century Companies first reported a position in Stoke Therapeutics in Q2 2019 and held it in 11 quarters.
American Century Companies's Stoke Therapeutics position peaked at $4.06M in Q4 2019.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.